Quarterly Result29 May 2026, 10:22 pm
Glenmark: FY26 Revenue Up 27.5% YoY to ₹169,825 Million
AI Summary
Glenmark Pharmaceuticals Ltd announced its Q4 and FY26 financial results, with FY26 consolidated revenue growing by 27.5% YoY to ₹169,825 million. The company secured a landmark licensing deal with AbbVie for ISB 2001, receiving USD 700 million upfront. Glenmark also expanded its oncology business in India and emerging markets. RYALTRIS® recorded over 50% growth in secondary sales. Q4 FY26 revenue reached ₹37,706 million, a 15.8% YoY increase, with a PAT of ₹3,013 million.
Key Highlights
- FY26 consolidated revenue grew 27.5% YoY to ₹169,825 million.
- Q4 FY26 consolidated revenue increased by 15.8% YoY to ₹37,706 million.
- AbbVie licensing deal for ISB 2001 includes USD 700 million upfront payment.
- RYALTRIS® secondary sales grew over 50% across commercial markets in FY26.
- FY26 PAT stood at ₹13,620 million with a PAT margin of 7.8%.
Price Impact
More from GLENMARK